Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease

2024-9-12

The microglial P2Y6 receptor as a therapeutic target for neurodegenerative diseases

2024-9-7

Neurodegenerative disorders, metabolic icebergs, and mitohormesis

2024-9-6

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

2024-9-4

A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease

2024-9-3

Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures

2024-8-27

Trajectory of brain-derived amyloid beta in Alzheimer’s disease: where is it coming from and where is it going?

2024-8-19

SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system

2024-8-9

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

2024-8-6

Neuronal double-stranded DNA accumulation induced by DNase II deficiency drives tau phosphorylation and neurodegeneration

2024-8-2

Linking APOE4/4 genotype to microglial lipid droplets and neurotoxicity in Alzheimer’s disease

2024-7-30

Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy

2024-7-29

Can exercise benefits be harnessed with drugs? A new way to combat neurodegenerative diseases by boosting neurogenesis

2024-7-25

Dorsal raphe nucleus–hippocampus serotonergic circuit underlies the depressive and cognitive impairments in 5×FAD male mice

2024-7-24

Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease

2024-7-24

Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer’s Disease

2024-6-27

Central nervous system-derived extracellular vesicles: the next generation of neural circulating biomarkers?

2024-6-19

DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease

2024-6-11

Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism

2024-6-5

In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use

2024-6-3

Variability in SOD1-associated amyotrophic lateral sclerosis: geographic patterns, clinical heterogeneity, molecular alterations, and therapeutic implications

2024-5-29

The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer’s disease

2024-5-28

CSF biomarkers of reactive glial cells are associated with blood–brain barrier leakage and white matter lesions

2024-5-23

Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease

2024-5-21

Agomirs upregulating carboxypeptidase E expression rescue hippocampal neurogenesis and memory deficits in Alzheimer’s disease

2024-4-26

Focusing on mitochondria in the brain: from biology to therapeutics

2024-4-17

The role of the brain renin-angiotensin system in Parkinson´s disease

2024-4-15

CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy

2024-4-12

Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis

2024-4-11

Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics

2024-4-9

Whole-brain dopamine transporter binding pattern predicts survival in multiple system atrophy

2024-4-2

Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms

2024-4-2

Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration

2024-3-26

Biases in α-synuclein immuno-quantitation: a core problem for basic and ancillary studies of Parkinson’s disease and multiple system atrophy

2024-3-25

Putative novel CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort

2024-3-8

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

2024-3-4

Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside

2024-2-27

α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes

2024-2-21

Emerging role of senescent microglia in brain aging-related neurodegenerative diseases

2024-2-20

Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease

2024-2-9

Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey

2024-2-6

The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing

2024-1-23

The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases

2024-1-22

Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau

2024-1-11

Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease

2024-1-9

Increased cysteinyl-tRNA synthetase drives neuroinflammation in Alzheimer’s disease

2024-1-8

Nanotechnology for microglial targeting and inhibition of neuroinflammation underlying Alzheimer’s pathology

2024-1-4

Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease

2024-1-3

Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies

2023-12-15

Supplementation with high-GABA-producing Lactobacillus plantarum L5 ameliorates essential tremor triggered by decreased gut bacteria-derived GABA

2023-12-13